Search

Your search keyword '"Verboom, Diana M."' showing total 11 results
Start Over Author "Verboom, Diana M." Publication Type Academic Journals
11 results on '"Verboom, Diana M."'

2. Consumptive coagulopathy is associated with a disturbed host response in patients with sepsis

Author

van Vught, Lonneke A., Uhel, Fabrice, Ding, Chao, van‘t Veer, Cees, Scicluna, Brendon P., Peters‐Sengers, Hessel, Klein Klouwenberg, Peter M.C., Nürnberg, Peter, Cremer, Olaf L., Schultz, Marcus J., van der Poll, Tom, de Beer, Friso M., Bos, Lieuwe D.J., Glas, Gerie J., Hoogendijk, Arie J., van Hooijdonk, Roosmarijn T.M., Horn, Janneke, Huson, Mischa A., Schouten, Laura R.A., Straat, Marleen, Wieske, Luuk, Wiewel, Maryse A., Witteveen, Esther, Bonten, Marc J.M., Cremer, Olaf M., Ong, David S.Y., Frencken, Jos F., Koster‐Brouwer, Maria E., van de Groep, Kirsten, and Verboom, Diana M.

Published
2021
Full Text
View/download PDF

6. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study

Author

de Beer, Friso M., Bos, Lieuwe D.J., Frencken, Jos F., Koster-Brouwer, Maria E., van de Groep, Kirsten, Verboom, Diana M., Glas, Gerie J., van Hooijdonk, Roosmarijn T.M., Hoogendijk, Arie J., Huson, Mischa A., Klouwenberg, Peter M. Klein, Ong, David S.Y., Schouten, Laura R.A., Straat, Marleen, Witteveen, Esther, Wieske, Luuk, Scicluna, Brendon P, van Vught, Lonneke A, Zwinderman, Aeilko H, Wiewel, Maryse A, Davenport, Emma E, Burnham, Katie L, Nürnberg, Peter, Schultz, Marcus J, Horn, Janneke, Cremer, Olaf L, Bonten, Marc J, Hinds, Charles J, Wong, Hector R, Knight, Julian C, and van der Poll, Tom

Published
2017
Full Text
View/download PDF

10. Detection of Invasive Aspergillosis in Critically Ill Patients with Influenza: The Role of Plasma Galactomannan.

Author

van de Groep, Kirsten, Verboom, Diana M., van de Veerdonk, Frank L., Haas, Pieter-Jan A., van der Poll, Tom, Schultz, Marcus J., Bonten, Marc J. M., and Cremer, Olaf L.

Abstract

The article discusses Invasive pulmonary aspergillosis (IPA) is a complication of influenza infection that has associated with 33–67% mortality. Topics include consensus criteria, IPA has diagnosed on the basis of clinical and radiological criteria in combination with the identification of Aspergillus species to growth in BAL fluid, and the aggregated 17% occurrence of influenza-associated IPA observed to comparable to the 19% incidence reported by Schauwvlieghe.

Published
2019
Full Text
View/download PDF

11. Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies.

Author

Verboom DM, van der Houwen TB, Kappen JH, van Daele PLA, Dik WA, Schreurs MWJ, van Hagen PM, and van Laar JAM

Subjects
Drug Resistance, Humans, Tumor Necrosis Factor-alpha antagonists & inhibitors, Adalimumab therapeutic use, Behcet Syndrome drug therapy, Immunosuppressive Agents therapeutic use
Abstract

Objectives: The TNF-blocker adalimumab can be effective in Behçet's disease (BD), a multisystem auto-inflammatory disorder. Unfortunately, the therapeutic efficacy of TNF-blockers can be hampered by the formation of anti-drug antibodies. We present an observational study of adalimumab in refractory BD with measurement of anti-drug antibodies., Methods: The effect of fortnightly 40mg adalimumab in nine patients with therapy refractory mucocutaneous, non-ocular or organ threatening BD was studied up to 60 months. Primary endpoint was a decrease in disease activity, measured by the BD Current Activity Form (BDCAF) within 6 months. Secondary endpoints included serum cytokines and the long-term formation of anti-adalimumab antibodies., Results: BDCAF improved significantly in all nine patients from 5.4 (SD=1.4) to 2.4 (SD=1.4) (p=0.007) within one month up to 6 months and after prolonged follow up of 5 years. All patients could either taper or stop concomitant therapy. Symptoms of mucocutaneous lesions, erythema nodosum and joint involvement decreased or disappeared. Serum TNF-alpha levels were elevates in five patients and decreased upon treatment (p=0.017). Adalimumab was save and none of the patients experienced therapy failure or antibodies against adalimumab., Conclusions: We present an observational study on patients with BD treated with adalimumab and provide a basis for long-term use in refractory mucocutaneous BD. These findings show that adalimumab can safely be administered yielding sustainable clinical effects in refractory BD patients with mucocutaneous disease without formation of anti-adalimumab antibodies, even after long follow up.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results